Business Plan

Let Drugs Become NFTs, So Everyone Participating in Their R&D Can Benefit

Build the World's Earliest Decentralized Pharma Infrastructure

Making Drugs into NFTs, So Everyone Involved in Their R&D Can Benefit

Seed Round Funding Request

Financing 2 Million RMB (or Equivalent USDT)

Market Size

Global Drug R&D Market $200 Billion/Year, China RWD Market $5 Billion/Year

Existing Data Barriers

8 Types of Continuous Data

Examination, biochemical, medication, body sensation, radiation, sleep, voice, emotion

Target Users

500+ Trial Records

Achieved in 12-24 Months, Continuous RWD Tracking

Drug-NFT Minting

50+ Drugs

Each Drug Corresponds to an NFT Equity Pool

Market Size

$200 Billion

Global Drug R&D Market/Year

Industry Pain Points and Opportunities

Let Drugs Become NFTs, So Everyone Participating in Their R&D Can Benefit

Critical

Subject Recruitment Difficulties

Extremely High Cost: Average 30,000-50,000 RMB per subject recruited
Long Cycle: Average 8-12 Months
Difficult Matching: Incomplete Health Profiles, Low Screening Efficiency

High

Real World Data Missing

Fragmented Data: Cannot Be Integrated Across Institutions and Platforms
Poor Continuity: Lack of Long-Term Trend Tracking
Uncontrollable Quality: High Manual Entry Error Rate

Critical

Incentive Mechanism Gap

No Return for Contributors: Patients and Doctors Give Data for Free
Monopoly Profits for Pharma: No Profit Sharing After Successful R&D
Zero Transparency: Black Box Process, Cannot Be Audited

Why Now?

FDA Policy Favorable

Regulatory Support

FDA Clearly Encouraged RWD Entry into Drug Registration Process in 2023

Web3 Infrastructure Mature

Technology Ready

Over 1,000+ Web3 GMP Pharma Projects Have Begun Sprouting Globally

DCT Acceptance Increasing

Market Education

Decentralized Clinical Trials (DCT) Recognition Increasing in China and International Markets

AI Dependence on RWD

Demand Explosion

AI-Driven Drug R&D Demand for Real World Data Is Unprecedented

Drug-NFT Core Mechanism

From Data Providers to Drug Asset Holders

Step 1

Pharma Mints Drug-NFT

Each Drug (or Clinical Trial) Corresponds to an NFT, Representing the Equity Pool (Value Pool) of That Drug's R&D Stage

Step 2

Contributors Receive Token/NFT

Patients Provide RWD, Doctors Evaluate, Researchers Contribute Algorithms, Receive Token or NFT Revenue Sharing Based on Contribution Share

Step 3

Data Becomes Assets

Patients' Data No Longer 'Given Away for Free', But Becomes Long-Term Assets That Can Provide Continuous Returns, Enjoying 1-3% Incentive Pool Revenue Sharing

Step 4

Full Process Transparency

All Contribution Records on Chain (De-identified), All Revenue Distribution Public, Drug R&D Stage Data Auditable

Contributor Roles and Rewards

All contributors become co-holders of 'drug assets', sharing long-term benefits

Patients/Trial Participants

Highest Value Contributors

Contribution

Provide Continuous Real World Data (RWD)

Symptom Records
Body Sensation Tracking
Medication Adherence Rate
Side Effect Events

Reward

NFT Allocation + Token Holdings + Pharma Subsidies + Post-Market Returns (1-3% Pool)

Doctors

Quality Assurance Layer

Contribution

Provide Professional Evaluation and Treatment Feedback

Efficacy Evaluation
Dosage Recommendations
Side Effect Judgment
Treatment Plan Optimization

Reward

Professional Service Split + Token Rewards

Researchers/Developers

Technology Driver Layer

Contribution

Contribute Analysis Models and Algorithm Plugins

Data Analysis Models
AI Prediction Algorithms
Indicator Insight Tools
Side Effect Early Warning Systems

Reward

Algorithm Token Rewards + NFT Royalties

WellAlly Platform

Infrastructure

Contribution

Provide Data Infrastructure and Matching System

Structured Data
Identity Management
Intelligent Matching
Continuity Verification

Reward

B-Side Service Fees + Token Rebates + Ecosystem Splits

TOB Business Model (Pharma Side)

Diversified Revenue Streams Covering Full Drug R&D Lifecycle

Trial Recruitment Service

Recruiting-as-a-Service

Provide Precise Subject Recruitment and Management for Pharmaceutical Companies

Features

Multi-Dimensional Health Profile Matching (Examination, Body Sensation, Medication History)
Identity Authentication + Compliance Review
Adherence Rate Tracking + Automatic Reminders
Trial Cycle Data Structured Upload

Short-Term Cash Flow

Continuous Real World Data

Continuous RWD Service

Provide Long-Term, Continuous, High-Quality Real World Data

Features

Continuous Biochemical Indicator Trends
Medication Adherence Rate Monitoring
Symptom, Body Sensation Record Changes
Side Effect Events (AE/SAE) Structured Reporting

Stable Income

Drug-NFT Incentive System

Tokenomics-as-a-Service

Build Web3 Incentive Ecosystem for Pharma Companies

Features

Drug Equity NFT Minting
Revenue Sharing Model Design
Contribution Attribution Mechanism
Distributed Data Collection Chain (Data Oracle)

Maximum Long-Term Value

TOC Patient Value Proposition

First Implementation: Trial Participation = Payment + Asset Rights

Immediate Returns

Immediate Redemption

Trial Subsidies (Fiat) + Health Management

Token Rewards

Continuous Incentives

Continuous Data Upload Receive Token

NFT Rights

Asset Appreciation

NFT Holdings Revenue Sharing, Long-Term Returns

Post-Market Returns

Maximum Returns

1-3% Incentive Pool After Drug Commercialization

Technical System Architecture

Building on WellAlly's existing capabilities, adding blockchain and DID layers

Data Layer

Completed

WellAlly Existing Capabilities Directly Reusable

OCR Report Structuring

Biochemical Indicator Trend Calculation

Medication Adherence Rate Tracking

Body Sensation Record Time Series Analysis

Clinic Recording Structure Extraction

Identity Layer

In Development

Patient Decentralized Identity (DID)

Privacy Protection Identity Authentication

Anonymous Matching System

Zero-Knowledge Proof Authorization

Multi-Institution Identity Mutual Recognition

Blockchain Layer

Design Phase

Smart Contracts + NFT System

Drug-NFT Minting and Management

Token Distribution Smart Contracts

Contribution Attribution Algorithms

Automatic Revenue Distribution

RWD Engine

30% Completed

Real World Data Quality Engine

Continuity Scoring Algorithms

Data Integrity Verification

Outlier Detection

Adherence Rate Calculation Models

Matching Engine

Design Phase

Intelligent Matching System

Multi-Dimensional Health Profile Matching

Trial Condition Screening

Geographic Location Optimization

Historical Data Quality Assessment

Competitive Advantages

Four-layer moat: data, mechanism, ecosystem, and compliance

Data Barrier (Strongest Moat)

Irreproducible

Industry's Hardest 'Continuous Real Data' Already Mastered: Structured Examinations, Biochemical Curves, Medication Adherence Rates, Body Sensation Records, Emotional Fluctuations, Sleep, Voice Clinic Visits, Radiation Dosage

Mechanism Barrier

First-Mover Advantage

Incentivize Data Rather Than Collect Data, Creating Data Value So Patients Are Willing to Provide Continuously, This Is a Paradigm Shift

Ecosystem Barrier

Network Effect

Simultaneously Connect Three Value Chains of Pharma (Demand Side), Patients (Supply Side), and AI (Analysis Side), WellAlly Is the Data Bus (Bus)

Compliance Barrier

Regulatory Friendly

De-Diagnosis Design, Data De-Identification, Zero-Knowledge Proof Authorization, Does Not Touch 'Trial Intermediary' Sensitive Terms, Fully Compliant

Implementation Roadmap

Three-phase plan: recruitment platform → continuous RWD → full Drug-NFT ecosystem

In Progress

Phase 1

0-6 Months

Trial Recruitment Platform Online

Key Objectives

Complete TOB-Side System Development
Complete Drug-NFT Core Contracts
Complete 50-100 Trial Matching
Establish 1-2 Pharma Pilot Partnerships

Milestone

First Drug-NFT Successfully Minted

Planning

Phase 2

6-12 Months

Continuous RWD Platform Online

Key Objectives

Form Continuous Data Indicator Models
Establish Partnerships with 3-5 Pharma Companies
Complete 200+ Trial Records
Token Incentive System Test Run

Milestone

RWD Subscription Revenue Reaches 1 Million/Year

Vision

Phase 3

12-24 Months

Drug-NFT Full Process Implementation

Key Objectives

Complete 500+ Trial Records
Drug NFT Minting Count Reaches 50+
Token Incentive Complete Positive Cycle
First Drug Post-Market Revenue Distribution

Milestone

Become China's Largest Decentralized Pharma Platform

Financing Plan and Fund Usage

Funding Request

2 Million RMB

or Equivalent USDT

Pre-money

Pre-money: 20 Million

Equity Offered

10%

Post-Money Valuation

2200 万

Post-money

Fund Allocation

Blockchain Contract Development & NFT System

30%

600,000 RMB

RWD Continuous Data Engine R&D

25%

500,000 RMB

Pharma BD & Compliance Review

20%

400,000 RMB

User Operations (Trial Participants)

10%

200,000 RMB

Medical Cooperation & Expert Advisory

10%

200,000 RMB

Servers & Privacy Computing

100,000 RMB

Financial Projections

Year 1

Revenue

500,000 RMB

User Scale

100 Trial Records

Pilot Verification, Establish Benchmark Cases

Year 2

Revenue

3 Million RMB

User Scale

500 Trial Records

Scaled Expansion, RWD Subscription Revenue Takeoff

Year 3

Revenue

12 Million RMB

User Scale

2,000+ Records

Drug-NFT Ecosystem Mature, Token Economy Closed Loop

Risk Analysis and Mitigation

Proactive identification and management of key risks

Regulatory Risk

Medium

Controllable

Mitigation Strategy

De-Diagnosis Design, Data De-Identification, Avoid 'Trial Intermediary' Sensitive Terms, Legal Team Continuous Review

Pharma Acceptance

Medium

Strategic Response

Mitigation Strategy

Pilot with Leading Innovative Pharma Companies, Provide Traditional Services as Foundation, Gradually Introduce Web3 Incentives

Technical Complexity

Low

Controllable

Mitigation Strategy

WellAlly 80% Technology Already Completed, Only Need to Add Blockchain Layer, Strong Team Technical Capability

Market Education Cost

Medium

Phased

Mitigation Strategy

Attract Patients with 'Subsidies + Assets' Dual Appeal, Anchor Pharma Value with 'Cost Reduction and Efficiency Improvement'

Team Advantages

Super Founder

0 Team Completed Product Listing, Extremely Strong Execution

Triple Background in Technology + Business + Healthcare

Overseas Validation: 200+ Users Natural Growth in 30 Days

Data Thinking: Already Mastered 8 Types of Continuous Health Data

Recruiting Key Positions

Blockchain Engineer

Senior

Smart Contracts + NFT System

Pharma BD

Mid-Senior

Pharma Industry Resources and Partnerships

Compliance Advisor

Advisor

Medical Data Compliance and Legal Review

One-Sentence Summary

WellAlly Is Doing the World's Earliest Decentralized Pharma Infrastructure, Making Real World Data Part of Drug Assets, So That Everyone Participating in Drug Growth Can Gain Returns.